Lack of Evidence Does Not Equal Lack of Benefit: Neoadjuvant Chemotherapy and Trimodality Therapy in Selected Patients with Muscle-Invasive Bladder Cancer : In response to: Dirk Böhmer and Arne Grün. Lacking Evidence to Recommend Neoadjuvant Chemotherapy and Definitive Radiotherapy in Muscle-Invasive Bladder Cancer.

Di Maria Jiang, Peter Chung, Girish S Kulkarni, Nick D James, Srikala S Sridhar

Abstract readEditorialComment

In one paragraph

Article in Current oncology reports, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it

0cells of the map it votes in

1citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

Combined Modality Bladder-Sparing Therapy for Muscle-Invasive Bladder Cancer: How (Should) We Do It? A Narrative Review.Journal of clinical medicine · 2023
Review

4 · The record

Corrections and comments

Comment on
Lacking Evidence to Recommend Neoadjuvant Chemotherapy and Definitive Radiotherapy in Muscle-Invasive Bladder Cancer : In response to: Trimodality Therapy for Muscle-Invasive Bladder Cancer: Recent Advances and Unanswered Questions published by Di Maria Jiang et al. Current Oncology Reports 2020, https://doi.org/10.1007/s11912-020-0880-5.2021

5 · Who and what money

Authors and funding

5 authors.

Di Maria JiangDepartment of Medicine, Division of Medical Oncology, Princess Margaret Cancer Center, University Health Network, University of Toronto, 700 University Avenue, Toronto, Ontario, M5G 6M9, Canada.

Peter ChungRadiation Medicine Program, Princess Margaret Cancer Centre, Department of Radiation Oncology, University of Toronto, Toronto, Canada.

Girish S KulkarniDivision of Urology, Departments of Surgery and Surgical Oncology, Princess Margaret Cancer Centre, University Health Network, University of Toronto, Toronto, Ontario, Canada.

Nick D JamesRadiotherapy and Imaging Division, The Institute of Cancer Research, London, UK.

Srikala S SridharDepartment of Medicine, Division of Medical Oncology, Princess Margaret Cancer Center, University Health Network, University of Toronto, 700 University Avenue, Toronto, Ontario, M5G 6M9, Canada. srikala.sridhar@uhn.ca.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Urinary Bladder NeoplasmsChemotherapy, AdjuvantCystectomyHumansMusclesNeoadjuvant Therapy

Identifiers

PMID33660142

DOI10.1007/s11912-021-01035-9

What OpenQuestion holds

Textmetadata

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.